You are here

Article Text

Article menu
Heart failure and cardiomyopathies
Original research
Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation
  1. Shohei Moriyama1,
  2. Mitsuhiro Fukata1,
  3. Michinari Hieda1,
  4. Taku Yokoyama1,
  5. Goichi Yoshimoto1,
  6. Hitoshi Kusaba1,
  7. Yasuhiro Nakashima2,
  8. Toshihiro Miyamoto3,
  9. Toru Maruyama4 and
  10. Koichi Akashi1
  1. 1Department of Haematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan
  2. 2Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  3. 3Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan
  4. 4Center for Health Sciences and Counseling, Kyushu University, Fukuoka, Japan
  1. Correspondence to Dr Mitsuhiro Fukata; fukata.mitsuhiro.555{at}m.kyushu-u.ac.jp

Abstract

Objective Heart failure following allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a serious complication that requires early detection; however, the clinical implications of early-onset cancer therapy-related cardiac dysfunction (CTRCD) following allo-HSCT remain unclear. We investigated the determinants and prognostic impact of early-onset CTRCD in allo-HSCT recipients.

Methods The records of 136 patients with haematological malignancies who underwent allo-HSCT at our institute were retrospectively reviewed. Early-onset CTRCD was defined as a decrease in left ventricular ejection fraction (LVEF) of ≥10% and an LVEF of ≤53% within 100 days after HSCT.

Results Early-onset CTRCD was diagnosed in 23 out of 136 included patients (17%), and the median duration from HSCT to CTRCD diagnosis was 24 (9–35) days. Patients were followed up for 347 (132–1268) days. In multivariate logistic regression analysis, cumulative doxorubicin dosage (each 10 mg/m2) and severity of acute graft-versus-host disease (GVHD/grade) were independent indicators of early-onset CTRCD (OR (95% CI) 1.04 (1.00 to 1.07); p=0.032; OR (95% CI) 1.87 (1.19 to 2.95), p=0.004, respectively). The overall and primary disease death rates were significantly higher in allo-HSCT recipients with early-onset CTRCD than in those without early-onset CTRCD (HR (95% CI) 1.98 (1.11 to 3.52), p=0.016; HR (95% CI) 2.96 (1.40 to 6.29), p=0.005, respectively), independent of primary disease type, remission status and transplantation type.

Conclusions Severe acute GVHD and higher cumulative anthracycline are two significant determinants of early-onset CTRCD. Early-onset CTRCD following allo-HSCT regulates survival in patients with haematological malignancies.

  • cardiomyopathies
  • heart failure, systolic
  • risk factors

Data availability statement

Data are available upon reasonable request.

https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/openhrt-2022-002007

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    WHAT IS ALREADY KNOWN ON THIS TOPIC

    • Haematopoietic stem cell transplantation (HSCT) is a key treatment for refractory haematological malignancies.

    • The preconditioning therapy and cell transplantation can cause various complications that make patient management difficult and worsen prognosis.

    • Cancer therapy-related cardiac dysfunction (CTRCD) following HSCT can be a serious complication; however, the clinical implications of early-onset CTRCD in recipients of HSCT remain unclear.

    WHAT THIS STUDY ADDS

    • Severe acute graft-versus-host disease (GVHD) and higher cumulative anthracycline dose are independent risk factors for early-onset CTRCD after allogeneic HSCT.

    • Early-onset CTRCD aggravates the prognosis of patients with haematological malignancies who have undergone allogeneic HSCT.

    HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

    • Adequate immunosuppression for GVHD and preconditioning regimen alternative for anthracycline might preserve cardiac function.

    • Monitoring of cardiac function and early intervention or prophylactic therapy for heart failure have a potential to improve prognosis of the patients who undergo allogeneic HSCT.

    Introduction

    Haematopoietic stem cell transplantation (HSCT) is an effective therapy for malignant and non-malignant haematopoietic disorders. Its outcomes have dramatically improved following advances in transplantation procedures and supportive care, resulting in more long-term survivors who have undergone HSCT.1 In HSCT survivors, the incidence of cardiovascular diseases—such as heart failure (HF) and coronary artery disease—as well as their risk factors, is higher than that in the general population.2 3 High cardiovascular mortality in HSCT recipients suggests the importance of early cardiotoxicity detection in these patients.2 In patients who have undergone autologous HSCT, cardiotoxicity is mainly attributed to the direct toxic effects of the conditioning regimen; in recipients who have undergone allogeneic HSCT (allo-HSCT), it is also caused by the indirect effects of graft-versus-host disease (GVHD) and immunosuppressive therapy.4 5 As a cause of cardiac dysfunction in HSCT recipients, anthracyclines have well-known dose-dependent cardiotoxicity3; however, there is scarcity of evidence regarding other causes of cardiac dysfunction following HSCT. Since cardiac dysfunction after HSCT can be potentially lethal, its early appropriate management is considered critical for patient survival. Therefore, the relevant clinical factors for and the impact of early-onset cardiac dysfunction on patient prognosis need to be investigated.6 7

    Recently, left ventricular systolic dysfunction after cancer therapy, detected by a decrease in left ventricular ejection fraction (LVEF), was defined as cancer therapy-related cardiac dysfunction (CTRCD). Therefore, periodic monitoring of LVEF via echocardiography is recommended for patients with cancer.8 9 Although several reports have described cardiotoxic events after HSCT,10 11 a definition for CTRCD in a recent consensus was not employed, and the relationship between left ventricular dysfunction at an early period following allo-HSCT and mortality has not been elucidated in these studies. Thus, we sought to clarify the incidence of early-onset CTRCD and its predictors and their effect on patient prognosis.

    Methods

    Study design

    This single-centre, retrospective study included 416 consecutive patients who underwent allo-HSCT for haematological disease between January 2007 and December 2018 at Kyushu University Hospital. Patients with benign haematopoietic disease (n=65) in whom neutrophils were not engrafted after allo-HSCT (n=10), those whose echocardiograms had not been recorded prior to HSCT or within 100 days after HSCT (n=192), and those whose LVEF was ≤53% at the time of HSCT (n=13) were excluded; therefore, 136 patients were eligible for inclusion in the analysis (figure 1). The median follow-up period was 347 (132 to 1268) days.

    Figure 1
    Figure 1

    Patient screening and enrolment. The cohort comprised 416 consecutive patients who underwent allo-HSCT. patients who met at least one of the four exclusion criteria were excluded. A total of 136 patients (early-onset CTRCD, n=23; non-CTRCD, n=113) were included in the analysis. allo-HSCT, allogeneic haematopoietic stem cell transplantation; CTRCD, cancer therapy-related cardiac dysfunction; HSCT, haematopoietic stem cell transplantation; LVEF, left ventricular ejection fraction.

    Since the aim of this study was to investigate the predictors of early-onset CTRCD and its impact on patient prognosis, candidates for the predictors of early-onset CTRCD included common cardiac risk factors, anthracycline dosage and haematologically important factors for the management of patients who underwent HSCT. Overall survival (OS), treatment-related mortality and death due to underlying diseases were evaluated as prognostic indicators. The protocol of this study was approved by the internal review board (approval number: 2019–339), and patient consent was obtained via an opt-out method. This was a retrospective observational study, and patients or the public could not be involved in the design, conduct, reporting or dissemination plans of our study. All procedures performed in this study were in accordance with the principles of the updated Declaration of Helsinki (2013).

    Definitions

    Growing evidence suggests that cardiooncology is a contemporary, diverse and challenging field of clinical science, and terminology relating to this field is somewhat confusing; therefore, we defined the terminology used in this study.

    Early-onset CTRCD was defined as CTRCD occurring within 100 days after allo-HSCT; CTRCD was defined as a decrease in LVEF by ≥10% from baseline LVEF and an LVEF of ≤53% after HSCT, irrespective of baseline LVEF.9 The Teichholz method was adopted as the method to calculate LVEF. Echocardiography was performed and assessed by experienced cardiologists and echocardiographers. Baseline LVEF was assessed before the first chemotherapy session or at the first echocardiography at our hospital. Symptoms of HF were defined as dyspnoea or body oedema without other causes that can sufficiently explain the symptoms.

    Cardiac risk factors include diabetes, hypertension, dyslipidaemia and current smoking.12 Creatinine clearance at HSCT was calculated using the Cockcroft-Gault equation. Cumulative anthracycline doses were converted to doxorubicin equivalents using conversion factors of 0.83, 0.67, 5.0 and 4.0 for daunorubicin, epirubicin, idarubicin and mitoxantrone, respectively.13 The myeloablative conditioning regimen was defined as a conditioning regimen with total body irradiation at ≥5 Gy in a single dose, ≥8 Gy in fractionated doses or an oral busulfan equivalent of ≥8 mg/kg with cyclophosphamide or melphalan.14 15

    The disease status of haematological malignancies evaluated at the time of HSCT was categorised as complete remission (CR) or non-CR, irrespective of the status following prior HSCT. Disease relapse was defined as a haematologically detected relapse. Acute GVHD was defined as GVHD occurring within 100 days after HSCT and graded according to the standard criteria.16 Tacrolimus and cyclosporine were mainly administered for GVHD prophylaxis; other agents for GVHD prophylaxis included prednisolone, mycophenolate mofetil and methotrexate. Since tacrolimus can cause cardiomyopathy, it was incorporated as a variable. Treatment-related death was defined as death by GVHD, infection or other cancer therapy-related conditions, such as thrombotic microangiopathy and secondary cancer.

    Statistics analysis

    Continuous variables are presented as medians (IQR) and compared between groups using the Mann-Whitney U test. Discrete variables were analysed with a contingency table using Fisher’s exact test. Patient characteristics were analysed using logistic regression analysis. Additionally, multiple logistic regression analyses were performed to elucidate the independent values. OS was summarised using the Kaplan-Meier method with the log-rank test, and Cox proportional hazards models, adjusted for several independent clinical factors, were used to estimate mortality. Independent factors with a p value of <0.05 in the univariate analysis, or those considered clinically relevant, were included in the multivariate analysis; factors with a high correlation (>0.6) were excluded as covariate factors to avoid multicollinearity. All multivariate analyses were conducted after confirming the fitting of models. Statistical significance (p) was set at <0.05. All statistical calculations were performed using JMP PRO V.15.1.0 (SAS Institute, Cary, North Carolina).

    Results

    Patient characteristics

    Early-onset CTRCD was detected in 23 of the 136 patients (17%); symptomatic HF was observed in 11 of them, including three severe HF required ventilatory support. The median duration from HSCT to CTRCD diagnosis was 24 (9 to 35) days.

    The median age of the included patients was 51 (37 to 61) years at the time of HSCT, and there was no difference in age between the CTRCD and non-CTRCD groups (table 1). Creatinine clearance was significantly lower in the CTRCD group than in the non-CTRCD group (p=0.026). Baseline LVEF and other echocardiographic parameters were comparable in the two groups (online supplemental table 1). Proportion of the patients with renin-angiotensin system inhibitors or beta-blockers before HSCT was also similar between the two groups (p=0.311). There was no difference in cardiac biomarkers prior to HSCT.

    View this table:
    Table 1

    Patient characteristics

    Underlying diseases included acute myeloid (n=60), acute lymphoblastic leukaemia (n=21), chronic myeloid (n=2) and other types of leukaemia (n=15) as well as malignant lymphoma (n=35) and plasma cell neoplasm (n=3). Eighty-nine patients (65%) were categorised as non-CR at the time of HSCT. The sources of transplanted cells were bone marrow (n=58), cord blood (n=34) and peripheral blood (n=44) stem cells, including those from haploidentical donors (n=13). All recipients who underwent haploidentical peripheral blood stem cell transplantation had a non-CR status. The incidence of high-grade acute GVHD (grade III or IV) was significantly higher in the CTRCD group than in the non-CTRCD group (35% vs 14%, p=0.032).

    Change in LVEF after transplantation

    In all participants, LVEF decreased from 68% (63%–73%) to 63% (56%–72%) after HSCT (p<0.001). LVEF after HSCT was 41% (26%–50%) in patients with CTRCD and 66% (60%–73%) in those without CTRCD (p<0.0001) (online supplemental figure 1). LVEF reduction (LVEF at baseline—LVEF after HSCT) was 26% (17%–40%) in patients with CTRCD and 3% (-2%–8%) in those without CTRCD (p<0.001).

    Clinical indicators of early-onset CTRCD

    Among clinical factors, the haematopoietic cell transplantation-specific comorbidity index (HCT-CI; /point) was found to be significant predictors of early-onset CTRCD in univariate analysis (OR, 1.56; 95% CI 1.02 to 2.38; p=0.042) (table 2). Remarkably, the incidence of early-onset CTRCD was significantly associated with the severity of acute GVHD (grade; OR, 4.42; 95% CI 1.71 to 11.40; p=0.002). In addition, LVEF reduction was greater in patients with high-grade acute GVHD than in those with low-grade (grade I or II) GVHD (72–24 vs 3 (−2–10], p=0.045) (online supplemental figure 2). In multivariate analysis, cumulative doxorubicin dose (each 10 mg/m2; OR, 1.04; 95% CI 1.00 to 1.07; p=0.032) and the grade of acute GVHD (grade; OR, 1.87; 95% CI 1.19 to 2.95; p=0.004) had a significant association with early-onset CTRCD (table 2). This result was robust in multiple logistic regression models adjusting for age and sex (online supplemental table 2).

    View this table:
    Table 2

    Univariate and age-adjusted multivariate analysis of risk factors for early-onset CTRCD after HSCT

    Impact of early-onset CTRCD on prognosis

    The OS rate was significantly lower in recipients with early-onset CTRCD (median OS, 5.6 months; 95% CI 2.1 to 10.0 months) than in those without early-onset CTRCD (median OS: 20.5 months, 95% CI 11.5 to (not available) months; p<0.001; figure 2); additionally, early-onset CTRCD exaggerated overall death in unadjusted analysis (HR: 3.30, 95% CI 2.01 to 5.41; p<0.001; table 3). Among other underlying factors, a lower creatinine clearance level (p=0.012), non-leukaemia as the primary disease (p=0.038), non-CR status at HSCT (p=0.001), haploidentical peripheral blood stem cell transplantation (p=0.004), HCT-CI (/point; p<0.001) and the grade of acute GVHD (grade; p=0.006) were also found to significantly increase the risk of mortality (online supplemental table 3). Early-onset CTRCD significantly increased the risk of overall death even after adjusting for baseline backgrounds including age, sex, creatinine clearance, primary disease type, CR status, source of HSCT, HCT-CI and acute GVHD (HR, 1.98; 95% CI 1.11 to 3.52; p=0.016; table 3). In the CTRCD group, patients with HF symptoms had a poorer survival rate than asymptomatic patients (median OS, 2.4 (0.9 to 8.9) months vs 8.8 (1.9 to 26.2) months; p=0.006; online supplemental figure 3). HF medications (beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers) were initiated in 14 patients (61%) in the CTRCD group until the end of follow-up, and no significant difference in OS was observed between patients with CTRCD with HF medications and those without HF medications (median OS, 5.8 (1.4 to 11.6) months vs 2.5 (0.8 to 27.8) months; p=0.943).

    Figure 2
    Figure 2

    OS with respect to CTRCD. The median OS was significantly shorter in the CTRCD group than in the non-CTRCD group (p<0.001). CTRCD, cancer therapy-related cardiac dysfunction; HSCT, haematopoietic stem cell transplantation; N/A, not available; OS, overall survival.

    View this table:
    Table 3

    Association of CTRCD with overall or cause-specific death

    Regarding the cause of death, primary disease and treatment-related deaths were observed in 39 (29%) and 42 (31%) patients, respectively (online supplemental table 4). Early-onset CTRCD significantly increased the risk of primary disease death in both unadjusted (HR, 3.91; 95% CI 1.97 to 7.77; p<0.001) and adjusted analysis (HR, 2.96; 95% CI 1.40 to 6.29; p=0.005) (table 3, online supplemental table 5). As the number of events was relatively small, association of early-onset CTRCD and the risk of primary disease death was confirmed by multiple adjustment models (online supplemental table 6). The primary disease in 14 patients (61%) in the CTRCD group and 41 patients (36%) in the non-CTRCD group relapsed after HSCT in this study. The proportion of patients who relapsed after HSCT and underwent retransplantation was significantly lower in the CTRCD group than in the non-CTRCD group (0% vs 23%, p=0.046). Early-onset CTRCD increased the risk of treatment-related death (HR, 2.77; 95% CI 1.35 to 5.69; p=0.005) in unadjusted analysis; however, the association was not significant after adjustment for age, sex, HCT-CI and acute GVHD (HR, 1.78; 95% CI 0.84 to 3.78; p=0.131) (table 3, (online supplemental table 7).

    Discussion

    This study elucidated the predictors and prognostic impact of early-onset CTRCD after allo-HSCT in patients with haematological malignancies, and two major findings were identified. First, severe acute GVHD, in addition to high-dose cumulative anthracycline, was a significant indicator of early-onset CTRCD. Second, patients with early-onset CTRCD had insufficient OS with a higher primary disease mortality than those without early-onset CTRCD.

    Early-onset CRTCD and its indicators

    Hertenstein et al17 reported that LVEF reduced less than 55% in 13% of patients who underwent HSCT within 3 months after transplantation, which is a comparable rate to the incidence of early-onset CTRCD in this study. Another study showed that 30% and 6% of patients who underwent HSCT developed clinically diagnosed HF and severe acute cardiomyopathy, respectively.10 These results showed that myocardial injury and subsequent left ventricular dysfunction are not rare and may be a limiting factor for HSCT.

    Notably, grade of acute GVHD had a significant association with early-onset CTRCD. The graft versus host reaction was reported to have direct cardiotoxicity through donor T-cell infiltration into the myocardium as well as indirect toxicity due to cytokine release.18 We previously reported that serum tumour necrosis factor-α and interleukin-2 levels were elevated in acute GVHD.19 These cytokines were shown to aggravate cardiac function,20 whereas the immune response was suggested to be implicated in the pathogenesis of dilated cardiomyopathy.21 Additionally, the frequency of regulatory T cells and suppressive reaction of responder T cells decreased in patients with dilated cardiomyopathy.22 23 An inverse correlation between the number of regulatory T cells and the development of acute GVHD has also been reported in the previous studies.24 Therefore, impaired function of regulatory T cells in acute GVHD patients may lead to the activation of responder T cell-mediated immune reactions and subsequent inflammation in the myocardium, thereby inducing cardiac dysfunction. Since cases of acute GVHD-related cardiac dysfunction—recovered by increasing immunosuppressive therapy—have been reported,18 the optimisation of immunosuppressive drugs in patients with acute GVHD with CTRCD has the potential to improve patient prognosis by ameliorating cardiac function. Further research is needed to clarify the mechanism of GVHD in the development of CTRCD.

    Our study also demonstrated an association between the cumulative dose of anthracycline and early-onset CTRCD. Several mechanisms of anthracycline-related cardiomyopathy have been suggested, such as oxidative stress, redox cycling by iron complexes and genetic variants.25 A cumulative anthracycline dose of ≥250 mg/m2 has been demonstrated to increase the risk of HF by up to 10-fold.3 11 This dose dependency of anthracycline-induced cardiotoxicity was also confirmed in our study, which targeted the early phase following HSCT. As an alternative to anthracycline in a preconditioning regimen, the use of molecular targeted therapy, which is generally less cardiotoxic than anthracycline, may reduce adverse cardiac events following HSCT and should be considered.

    Early-onset CTRCD as a prognostic factor

    Early-onset CTRCD increased the risk of overall death by two-fold, and the HR for overall death was higher in patients with early-onset CTRCD than in those with a non-CR status. This suggests that early-onset cardiac dysfunction is a highly important determinant of recipient survival. As a cause of death, early-onset CTRCD has been shown to increase the risk of primary disease death more than double. One of the possible reasons for the high primary disease mortality in patients with CTRCD is the undertreatment of the primary disease. Treatment for refractory haematological malignancies after HSCT is performed with much difficulty due to decreased performance status, impaired immune system and tissue damage—including to the cardiovascular system—during prior treatment.16 As anthracycline should be reduced or discontinued in patients with cardiac dysfunction, patients with refractory haematological malignancies accompanied by early-onset CTRCD cannot receive sufficient treatment for underlying disease.26 In fact, none of the patients with early-onset CTRCD in our cohort underwent additional HSCT, even after relapse.

    Early detection and treatment of cardiac dysfunction are of great significance to avoid undertreatment of haematological malignancies caused by HF. Repeated examinations of biomarkers such as troponin and echocardiographic parameters including global longitudinal strain may be useful for early detection of cardiac injury.8 9 In this study, the prognosis of patients with HF symptoms was extremely poor, and the difference in OS between CTRCD patients who received or did not receive HF medications was not statistically significant. These results suggest that initiation of HF treatment after the onset of symptomatic HF is too late to improve patient outcomes. Combined treatment with a renin-angiotensin system inhibitor and a beta-blocker is proved to preserve LVEF and reduce cardiac events in patients with haematopoietic malignancies by the OVERCOME (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies) trial27; however, delayed initiation of HF treatment reduces therapeutic efficacy.28 Further research with a defined treatment protocol is needed to clarify the appropriate time to start the treatment of HF for patients with CTRCD.

    A recent study suggested that HF is induced or aggravated via inflammation provoked by somatic mutations associated with clonal haematopoiesis of indeterminate potential (CHIP), such as tet methylcytosine dioxygenase 2 (TET2) and deoxyribonucleic acid methyltransferase 3 alpha (DNMT3A).29 Patients with a CHIP mutation had a low survival rate, possibly due to anthracycline resistance30; therefore, the possibility that CHIP acts as a common background for cardiac dysfunction after HSCT and the refractoriness of haematological malignancies should be investigated in future studies.

    Limitations

    This study has some limitations. First, LVEF measured by the Teichholz method, which allows a potential off-axis measurement and has a relatively low accuracy of intra-LV volume presumption, was adopted. This is because LVEF from biplane image could not be measured in part of the recipients because of the difficulty in the apex approach in the lateral position due to poor physical status. Although CTRCD in this study was defined by only LVEF, detection of cardiac dysfunction by only LVEF poses a potential limitation as LVEF can be affected by volume status, preload and afterload. Subtle deterioration in LV systolic function may be better detected by the global longitudinal strain method.31 Second, this was a single-centre retrospective study with a limited number of patients, and patients without echocardiography before or after HSCT were excluded. As echocardiography was performed at a physician’s discretion, participant enrolment may have potentially led to a selection bias. The result that OS of the participants in this study was lower than that in the previous report of allogeneic HSCT17 might reflect higher proportion of patients with a serious condition in our participants. However, the incidences of CTRCD and severe acute GVHD were comparable to those in previous reports,17 32 33 suggesting that the participants in this study may not have been highly restricted distribution. Third, echocardiography was not performed in predefined schedule. To limit heterogeneity regarding the timing of echocardiography after HSCT, only cases who underwent echocardiography within 100 days after HSCT were included in this study. Forth, HF treatment was not performed using a predetermined protocol. Nevertheless, our study is one of the few studies limited to patients with malignant haematopoietic diseases who underwent allo-HSCT. Our finding that CTRCD defined by criteria reported in a recent consensus report determined the survival of HSCT recipients emphasised the importance of performing serial echocardiography in these patients. Future multicentre prospective trials will compensate for the limitations of this study and contribute to the investigation regarding the aetiology of and appropriate treatment for CTRCD, which could lead to improved prognosis in patients undergoing HSCT.

    Conclusion

    Our study identified severe acute GVHD as well as higher cumulative anthracycline as indicators of early-onset CTRCD. Additionally, early-onset CTRCD was an independent factor for poor prognoses with a higher primary disease mortality in recipients following allo-HSCT. Further research is needed to clarify the mechanism underlying the relationship between CTRCD and GVHD, an optimised regimen of less cardiotoxic cancer chemotherapy for patients with CTRCD and the appropriate time to initiate HF treatment in recipients of allo-HSCT.

    Data availability statement

    Data are available upon reasonable request.

    Ethics statements

    Patient consent for publication

    Ethics approval

    This study was approved by the internal review board in Kyushu University (approval number: 2019-339).

    Acknowledgments

    We gratefully acknowledge past and present staffs in our hospital for their clinical work and Editage for language editing.

    References

    1. ↵
      1. Copelan EA
      . Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–26.doi:10.1056/NEJMra052638pmid:http://www.ncbi.nlm.nih.gov/pubmed/16641398
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Chow EJ,
      2. Mueller BA,
      3. Baker KS, et al
      . Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011;155:21–32.doi:10.7326/0003-4819-155-1-201107050-00004pmid:http://www.ncbi.nlm.nih.gov/pubmed/21727290
      OpenUrlCrossRefPubMed
    3. ↵
      1. Armenian SH,
      2. Sun C-L,
      3. Shannon T, et al
      . Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011;118:6023–9.doi:10.1182/blood-2011-06-358226pmid:http://www.ncbi.nlm.nih.gov/pubmed/21976673
      OpenUrlAbstract/FREE Full Text
    4. ↵
      1. Atkison P,
      2. Joubert G,
      3. Barron A, et al
      . Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894–6.doi:10.1016/S0140-6736(95)90011-Xpmid:http://www.ncbi.nlm.nih.gov/pubmed/7535875
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      1. Dogan A,
      2. Dogdu O,
      3. Ozdogru I, et al
      . Cardiac effects of chronic graft-versus-host disease after stem cell transplantation. Tex Heart Inst J 2013;40:428–34.pmid:http://www.ncbi.nlm.nih.gov/pubmed/24082373
      OpenUrlPubMed
    6. ↵
      1. Cardinale D,
      2. Colombo A,
      3. Bacchiani G, et al
      . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981–8.doi:10.1161/CIRCULATIONAHA.114.013777pmid:http://www.ncbi.nlm.nih.gov/pubmed/25948538
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Murdych T,
      2. Weisdorf DJ
      . Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001;28:283–7.doi:10.1038/sj.bmt.1703133pmid:http://www.ncbi.nlm.nih.gov/pubmed/11535997
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Moriyama S,
      2. Fukata M,
      3. Kusaba H, et al
      . Acute and chronic effects of cancer drugs on the cardiovascular system. Heart Fail Clin 2020;16:231–41.doi:10.1016/j.hfc.2019.11.002pmid:http://www.ncbi.nlm.nih.gov/pubmed/32143767
      OpenUrlPubMed
    9. ↵
      1. Plana JC,
      2. Galderisi M,
      3. Barac A, et al
      . Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911–39.doi:10.1016/j.echo.2014.07.012pmid:http://www.ncbi.nlm.nih.gov/pubmed/25172399
      OpenUrlCrossRefPubMed
    10. ↵
      1. Cazin B,
      2. Gorin NC,
      3. Laporte JP, et al
      . Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986;57:2061–9.doi:10.1002/1097-0142(19860515)57:10&lt;2061::AID-CNCR2820571031&gt;3.0.CO;2-Hpmid:http://www.ncbi.nlm.nih.gov/pubmed/3513941
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      1. Fujimaki K,
      2. Maruta A,
      3. Yoshida M, et al
      . Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001;27:307–10.doi:10.1038/sj.bmt.1702783pmid:http://www.ncbi.nlm.nih.gov/pubmed/11277179
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Armenian SH,
      2. Lacchetti C,
      3. Barac A, et al
      . Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893–911.doi:10.1200/JCO.2016.70.5400pmid:http://www.ncbi.nlm.nih.gov/pubmed/27918725
      OpenUrlCrossRefPubMed
    13. ↵
      1. Shankar SM,
      2. Marina N,
      3. Hudson MM, et al
      . Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008;121:e387–96.doi:10.1542/peds.2007-0575pmid:http://www.ncbi.nlm.nih.gov/pubmed/18187811
      OpenUrlAbstract/FREE Full Text
    14. ↵
      1. Bacigalupo A,
      2. Ballen K,
      3. Rizzo D, et al
      . Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–33.doi:10.1016/j.bbmt.2009.07.004pmid:http://www.ncbi.nlm.nih.gov/pubmed/19896087
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. Giralt S,
      2. Ballen K,
      3. Rizzo D, et al
      . Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15:367–9.doi:10.1016/j.bbmt.2008.12.497pmid:http://www.ncbi.nlm.nih.gov/pubmed/19203728
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      1. Saad A,
      2. de Lima M,
      3. Anand S, et al
      . Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18:599–634.doi:10.6004/jnccn.2020.0021pmid:http://www.ncbi.nlm.nih.gov/pubmed/32519831
      OpenUrlPubMed
    17. ↵
      1. Hertenstein B,
      2. Stefanic M,
      3. Schmeiser T, et al
      . Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994;12:998–1004.doi:10.1200/JCO.1994.12.5.998pmid:http://www.ncbi.nlm.nih.gov/pubmed/8164054
      OpenUrlAbstract/FREE Full Text
    18. ↵
      1. Rackley C,
      2. Schultz KR,
      3. Goldman FD, et al
      . Cardiac manifestations of graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:773–80.doi:10.1016/j.bbmt.2005.07.002pmid:http://www.ncbi.nlm.nih.gov/pubmed/16182178
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      1. Miyamoto T,
      2. Akashi K,
      3. Hayashi S, et al
      . Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996;17:185–90.pmid:http://www.ncbi.nlm.nih.gov/pubmed/8640164
      OpenUrlPubMedWeb of Science
    20. ↵
      1. Prabhu SD
      . Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140–53.doi:10.1161/01.RES.0000150734.79804.92pmid:http://www.ncbi.nlm.nih.gov/pubmed/15591236
      OpenUrlAbstract/FREE Full Text
    21. ↵
      1. Schultheiss H-P,
      2. Fairweather D,
      3. Caforio ALP, et al
      . Dilated cardiomyopathy. Nat Rev Dis Primers 2019;5:32.doi:10.1038/s41572-019-0084-1pmid:http://www.ncbi.nlm.nih.gov/pubmed/31073128
      OpenUrlPubMed
    22. ↵
      1. Meng X,
      2. Yang J,
      3. Dong M, et al
      . Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol 2016;13:167–79.doi:10.1038/nrcardio.2015.169pmid:http://www.ncbi.nlm.nih.gov/pubmed/26525543
      OpenUrlPubMed
    23. ↵
      1. Tang H,
      2. Zhong Y,
      3. Zhu Y, et al
      . Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy. Heart 2010;96:765–71.doi:10.1136/hrt.2009.184945pmid:http://www.ncbi.nlm.nih.gov/pubmed/20448127
      OpenUrlAbstract/FREE Full Text
    24. ↵
      1. Koreth J,
      2. Matsuoka K-ichi,
      3. Kim HT, et al
      . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055–66.doi:10.1056/NEJMoa1108188pmid:http://www.ncbi.nlm.nih.gov/pubmed/22129252
      OpenUrlCrossRefPubMedWeb of Science
    25. ↵
      1. Rochette L,
      2. Guenancia C,
      3. Gudjoncik A, et al
      . Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 2015;36:326–48.doi:10.1016/j.tips.2015.03.005pmid:http://www.ncbi.nlm.nih.gov/pubmed/25895646
      OpenUrlCrossRefPubMed
    26. ↵
      1. Chang H-M,
      2. Moudgil R,
      3. Scarabelli T, et al
      . Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 2017;70:2536–51.doi:10.1016/j.jacc.2017.09.1096pmid:http://www.ncbi.nlm.nih.gov/pubmed/29145954
      OpenUrlFREE Full Text
    27. ↵
      1. Bosch X,
      2. Rovira M,
      3. Sitges M, et al
      . Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013;61:2355–62.doi:10.1016/j.jacc.2013.02.072pmid:http://www.ncbi.nlm.nih.gov/pubmed/23583763
      OpenUrlFREE Full Text
    28. ↵
      1. Cardinale D,
      2. Colombo A,
      3. Lamantia G, et al
      . Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–20.doi:10.1016/j.jacc.2009.03.095pmid:http://www.ncbi.nlm.nih.gov/pubmed/20117401
      OpenUrlFREE Full Text
    29. ↵
      1. Cremer S,
      2. Kirschbaum K,
      3. Berkowitsch A, et al
      . Multiple somatic mutations for clonal hematopoiesis are associated with increased mortality in patients with chronic heart failure. Circ Genom Precis Med 2020;13:e003003.doi:10.1161/CIRCGEN.120.003003pmid:http://www.ncbi.nlm.nih.gov/pubmed/32598856
      OpenUrlPubMed
    30. ↵
      1. Guryanova OA,
      2. Shank K,
      3. Spitzer B, et al
      . DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med 2016;22:1488–95.doi:10.1038/nm.4210pmid:http://www.ncbi.nlm.nih.gov/pubmed/27841873
      OpenUrlCrossRefPubMed
    31. ↵
      1. Oka T,
      2. Tada Y,
      3. Oboshi M, et al
      . Serial changes in cardiac strain and contractility after hematopoietic stem cell transplantation in patients with hematologic malignancies. Int Heart J 2021;62:575–83.doi:10.1536/ihj.20-434pmid:http://www.ncbi.nlm.nih.gov/pubmed/33994498
      OpenUrlPubMed
    32. ↵
      1. Gooley TA,
      2. Chien JW,
      3. Pergam SA, et al
      . Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–101.doi:10.1056/NEJMoa1004383pmid:http://www.ncbi.nlm.nih.gov/pubmed/21105791
      OpenUrlCrossRefPubMedWeb of Science
    33. ↵
      1. Jagasia M,
      2. Arora M,
      3. Flowers MED, et al
      . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296–307.doi:10.1182/blood-2011-06-364265pmid:http://www.ncbi.nlm.nih.gov/pubmed/22010102
      OpenUrlAbstract/FREE Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Twitter @mori__1986

    • Contributors SM and MF were responsible for the study conception and design; SM acquired data and drafted the manuscript; SM, MF, MH, TY, GY and YN analysed and interpreted the data; HK, TMi, TMa and KA supervised and discussed the findings of this work, and all authors reviewed the manuscript and approved the final version for submission. MF acts as a guarantor.

    • Funding This work was supported by JSPS KAKENHI, grant number JP17K11577.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.